HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coty’s First Refillable Fragrance Among 2022 Sustainability Highlights

Executive Summary

Chloé Rose Naturelle Intense, Coty’s first refillable fragrance, makes its 2022 sustainability report along with green science to replace D5 silicone and the company’s partnership with LanzaTech NZ to create fragrances using ethanol made from captured carbon emissions.

You may also be interested in...



Coty’s Consumer Biz Leads Q1 As Supply Issues, China Lockdowns Offset Prestige Beauty Demand

Fragrance component shortages and COVID-19 restrictions in China were among factors that dragged on Coty’s Prestige business growth in the first quarter of fiscal 2023. Nevertheless, the division’s sales rose 7% like-for-like, while Consumer Beauty grew 12% on the strength of restaged brands.

Global Beauty Consortium For Eco-Scoring Products Is 36 Companies Strong; Prototype By Year-End

The EcoBeautyScore Consortium, dedicated to launching an environmental scoring system for products, has grown to 36 cosmetics and personal care firms as well as trade groups across four continents, L’Oréal Groupe reports after unveiling the effort in September. A prototype is targeted for the end of 2022.

Coty’s FY 2023 Will Be ‘Year Of Skin Care’; Reinstated ‘Powerhouse’ Says Growth Engines Are Fired

Doubts about Coty’s “viability” have melted away with the return to growth of its Consumer Beauty division and momentum in its burgeoning skin-care and prestige cosmetics businesses. Coty now aims to beat the market with 6% to 8% compound annual revenue growth from fiscal 2022 through 2025.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel